{"text": "TITLE:\n      Phase 2 Extension Study of Ambrisentan in Pulmonary Arterial Hypertension\nSUMMARY:\n      AMB-220-E is an international, multicenter, open-label study examining the long-term safety\n      of ambrisentan (BSF 208075) in subjects who have previously completed Myogen study\n      NCT00046319, \"A Phase II, Randomized, Double-Blind, Dose-Controlled, Dose-Ranging,\n      Multicenter Study of BSF 208075 Evaluating Exercise Capacity in Subjects with Moderate to\n      Severe Pulmonary Arterial Hypertension\".\nELIGIBILITY CRITERIA:\n      Inclusion Criteria:\n          -  Must have completed Visit 14/Week 24 of the NCT00046319 study.\n          -  Women of childbearing potential must have a negative urine pregnancy test at the\n             Screening/Enrollment Visit and agree to use a reliable double barrier method of\n             contraception until study completion and for >=4 weeks following their final study\n             visit.\n          -  Must have completed the Down-titration Period of NCT00046319 prior to enrollment in\n             AMB-220-E and will meet the following additional criteria:\n          -  Subjects with a diagnosis of HIV must have stable disease status at the time of\n             Screening/Enrollment.\n          -  Must be stable on conventional therapy for PAH for >=4 weeks prior to the Screening\n             Visit.\n        Exclusion Criteria:\n          -  Chronic prostanoid therapy, or other investigational prostacyclin derivative within 4\n             weeks prior to the Screening Visit.\n          -  Intravenous inotrope use within 2 weeks prior to the Screening Visit.\n          -  Females who are pregnant or breastfeeding.\n          -  Contraindication to treatment with an endothelin receptor antagonist (ERA).\n", "cuis": "C0020538 C1963138 C3248638 C0947663 C0085580 C0455405 C1696708 C3829824 C1176329 C3854112 C0233494 C2707265 C0024109 C0041327 C0003842 C0947630 C1552616 C1706244 C0332128 C1705425 C0947630 C1176329 C0947630 C0006463 C2911690 C0180112 C0456909 C1561605 C1561606 C3897779 C1522704 C0452240 C1547226 C4049705 C4049706 C0947630 C0006463 C0020538 C1963138 C3248638 C0947663 C0085580 C0455405 C1696708 C3829824 C2707265 C0024109 C0041327 C0003842 C1547227 C1547231 C1561581 C4050465 C4050466 C0264097 C0243161 C0013893 C0243161 C0947630 C1512346 C0430056 C0373524 C0593623 C2188702 C1513916 C2222792 C0004764 C0558250 C1516879 C3888021 C0220908 C1710031 C0199230 C1409616 C1698960 C3858758 C1512346 C0700589 C0344221 C0493327 C0877698 C0086286 C0086580 C0947630 C1512346 C3888021 C1516879 C0162621 C0025344 C0013080 C0243161 C0559897 C0677946 C0011900 C0945731 C0551521 C0552426 C0560182 C0686906 C0679838 C1516879 C3888021 C0220908 C1710031 C0199230 C1409616 C1698960 C2945704 C0220908 C1710031 C0199230 C1409616 C1698960 C1512346 C0243161 C3245491 C1552578 C0013230 C0220825 C1261322 C0033567 C0205911 C2825061 C0699125 C0033554 C1547296 C1555457 C0087111 C0033972 C0606968 C0220908 C1710031 C0199230 C1409616 C1698960 C1512346 C0220908 C1710031 C0199230 C1409616 C1698960 C0304509 C0085297 C1512346 C0006147 C1623040 C1623041 C0549206 C1134681 C1516869 C1301624 C1547316 C3714732 C0087111 C3887704 C0376495 C1533734 C0746919 C0814472 C3647788 ", "concepts": "Hypertension NOS, Hypertension, Hypertension mg, Hypertensin, Hypertension NOS, FH: Hypertension, Pre-Hypertension, Has Hypertension, Ambrisentan, Extension, tension, Pulmonary, pulmonary, Pulmonary TB, Arterial, Study summary, summary examining, label, study ambrisentan, study, bsf Controlled, Controller, Blind, Blind, Blind, Randomiz Exercise, Exercises, Moderate, Moderate, Moderate, Study, bsf Hypertension NOS, Hypertension, Hypertension mg, Hypertensin, Hypertension NOS, FH: Hypertension, Pre-Hypertension, Has Hypertension, Pulmonary, pulmonary, Pulmonary TB, Arterial, Severe, Severe, Severe, Severe, Severe, Sever criteria, Eligibility Criteria study, Visits Urine pregnancy test, Urine pregnancy test, urine home pregnancy test, urine hCG, pregnancy test, Negative, OT potential barrier method, Male barrier method, Enrollment, enrollment, screening, screening, screening, screening, screening, reliable, Visits contraception, IUD contraception, CAP contraception, CAP contraception, Contraception;F, Contraception;M, study visit enrollment, Enrollment, titration, Period, Down criteria, diet following stable disease, diagnosis, Diagnosis, ED diagnosis, ED diagnosis, no diagnosis, No diagnosis, Misdiagnosis Enrollment, enrollment, screening, screening, screening, screening, screening conventional therapy, screening, screening, screening, screening, screening Visits Criteria investigational, investigation, investigational drug, Investigation, Investigation, prostacyclin, Prostacyclins, Prostacycline, Hostacyclin, prostanoid, Chronic, Chronic, therapy, Cotherapy, derivative V screening, screening, screening, screening, screening, Visits screening, screening, screening, screening, screening, inotropes, Intravenous IG, Visits breastfeedings, Breastfeeding, Breastfeeding, pregnant endothelin receptor antagonist, endothelin-1 protein receptor antagonist, contraindication, Contraindication, Contraindication, Treatment, treatment, Retreatment, Treatment, no treatment, co-treatment, maltreatment "}
